Embedding a membrane protein into an enveloped artificial viral replica - PubMed (original) (raw)
. 2021 Dec 21;3(2):231-241.
doi: 10.1039/d1cb00166c. eCollection 2022 Feb 9.
Affiliations
- PMID: 35360888
- PMCID: PMC8827153
- DOI: 10.1039/d1cb00166c
Embedding a membrane protein into an enveloped artificial viral replica
Hiroto Furukawa et al. RSC Chem Biol. 2021.
Abstract
Natural enveloped viruses, in which nucleocapsids are covered with lipid bilayers, contain membrane proteins on the outer surface that are involved in diverse functions, such as adhesion and infection of host cells. Previously, we constructed an enveloped artificial viral capsid through the complexation of cationic lipid bilayers onto an anionic artificial viral capsid self-assembled from β-annulus peptides. Here we demonstrate the embedding of the membrane protein Connexin-43 (Cx43), on the enveloped artificial viral capsid using a cell-free expression system. The expression of Cx43 in the presence of the enveloped artificial viral capsid was confirmed by western blot analysis. The embedding of Cx43 on the envelope was evaluated by detection via the anti-Cx43 antibody, using fluorescence correlation spectroscopy (FCS) and transmission electron microscopy (TEM). Interestingly, many spherical structures connected to each other were observed in TEM images of the Cx43-embedded enveloped viral replica. In addition, it was shown that fluorescent dyes could be selectively transported from Cx43-embedded enveloped viral replicas into Cx43-expressing HepG2 cells. This study provides a proof of concept for the creation of multimolecular crowding complexes, that is, an enveloped artificial viral replica embedded with membrane proteins.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
There are no conflicts of interest to declare.
Figures
Fig. 1. (A) Schematic illustration and (B) TEM images of enveloped viral capsid embedded with Cx43 ([β-annulus-EE] = 16 μM, [DOTAP] = 48 μM, [DOPC] = 480 μM). Cx43 was expressed from 17.3 to 34.6 nM pURE-Cx43 using the PURE system. The samples were stained with EM stainer.
Fig. 2. (A) Western blot analysis of Cx43 expressed from 17.3 nM pURE-Cx43 in the presence of enveloped viral capsid ([β-annulus-EE] = 16 μM, [DOPC] = 480 μM (DOTAP/DOPC = 0/10); [β-annulus-EE] = 16 μM, [DOTAP] = 9.6 μM, [DOPC] = 480 μM (DOTAP/DOPC = 0.2/10); [β-annulus-EE] = 16 μM, [DOTAP] = 24 μM, [DOPC] = 480 μM (DOTAP/DOPC = 0.5/10); [β-annulus-EE] = 16 μM, [DOTAP] = 48 μM, [DOPC] = 480 μM (DOTAP/DOPC = 1/10)) in 10 mM Tris–HCl buffer (pH 7.0). (B) Western blot analysis of the concentration dependence of pURE-Cx43 (0, 17.3, 34.6, 69.1 nM) in the presence of enveloped viral capsid ([β-annulus-EE] = 16 μM, [DOTAP] = 48 μM, [DOPC] = 480 μM (DOTAP/DOPC = 1/10)) in 10 mM Tris–HCl buffer (pH 7.0).
Fig. 3. (A) Normalised auto-correlation curves of 10 nM Alexa Fluor 488-labelled anti-Cx43 antibody in the presence of Cx43-embedded viral replica (red), free Cx43 (blue), and in the absence of Cx43 (antibody alone, green) in 10 mM Tris–HCl buffer (pH 7.0) at 25 °C. (B–D) Measured (solid) and fitted (dot) auto-correlation curves of 10 nM Alexa Fluor 488-labelled anti-Cx43 antibody in the presence of (B) Cx43-embedded viral replica ([β-annulus-EE] = 4 μM, [DOTAP] = 12 μM, [DOPC] = 120 μM) or (C) free Cx43, and (D) in the absence of Cx43 (the antibody alone). Cx43 was expressed from 17.3 nM pURE-Cx43 using the PURE system.
Fig. 4. Concentration dependence of Alexa Fluor 488-labelled anti-Cx43 antibody on the ratio of the slow component determined by FCS curve fitting in the presence of (A) free Cx43 and (B) Cx43-embedded viral replica ([β-annulus-EE] = 4 μM, [DOTAP] = 12 μM, [DOPC] = 120 μM) at 25 °C. Cx43 was expressed from 17.3 nM pURE-Cx43 using the PURE system. Binding curve of the antibody to Cx43 is characterised by the Langmuir equation.
Fig. 5. TEM images of (A) anti-Cx43 antibody (42 nM) and the gold nanoparticle-labelled secondary antibody (14.8 nM) against anti-Cx43 antibody, the mixture of the anti-Cx43 antibody and the gold nanoparticle-labelled secondary antibody with (B) the enveloped viral capsid ([β-annulus-EE] = 4 μM, [DOTAP] = 12 μM, [DOPC] = 120 μM), (C) Cx43-embedded viral replica ((DOTAP/DOPC = 1/10) [β-annulus-EE] = 4 μM, [DOTAP] = 12 μM, [DOPC] = 120 μM), and (D) Cx43-expressed liposome ([DOTAP] = 12 μM, [DOPC] = 120 μM) in 10 mM Tris–HCl buffer (pH 7.0). Cx43 was expressed from 17.3 nM pURE-Cx43 using PURE system. TEM samples were stained with EM stainer. Red arrows indicate the gold nanoparticle-labelled secondary antibody.
Fig. 6. TEM images of anti-Cx43 antibody (42 nM) and the gold nanoparticle-labelled secondary antibody (14.8 nM) against anti-Cx43 antibody under the Cx43-embedded viral replica ((DOTAP/DOPC = 1/10) [β-annulus-EE] = 4 μM, [DOTAP] = 12 μM, [DOPC] = 120 μM) in 10 mM Tris–HCl buffer (pH 7.0). Cx43 was expressed from 34.6 or 69.1 nM pURE-Cx43 using PURE system. TEM samples were stained with EM stainer. Red arrows indicate the gold nanoparticle-labelled secondary antibody.
Fig. 7. Transport of 5-TMR from Cx43-embedded viral replica into HepG2 cells. (A) CLSM images of HepG2 cells incubated with 5 μM Alexa Fluor 488-labelled anti-Cx43 antibody. Channels for Alexa Fluor 488 (green), Hoechst 33342 (cyan), and bright field for CLSM images. (B) CLSM images of HepG2 cells incubated with 5-TMR-encapsulated Cx43-embedded viral replica or enveloped capsid without Cx43 ([β-annulus-EE] = 10 μM, [DOTAP] = 30 μM, [DOPC] = 300 μM, [5-TMR] = 1.7 μM). Cx43 was expressed from 17.3 nM pURE-Cx43 using PURE system. Channels for 5-TMR (magenta) and Hoechst 33342 (cyan) for CLSM images. (C) Box plot of the fluorescence intensity distribution of 5-TMR in HepG2 cells normalised outside of cells (N = 60). The _P_-value was calculated by one-way analysis of variance followed by Mann–Whitney U test.
Similar articles
- A supramolecular system mimicking the infection process of an enveloped virus through membrane fusion.
Furukawa H, Kimura Y, Inaba H, Matsuura K. Furukawa H, et al. Sci Rep. 2023 Nov 15;13(1):19934. doi: 10.1038/s41598-023-47347-7. Sci Rep. 2023. PMID: 37968508 Free PMC article. - Enveloped artificial viral capsids self-assembled from anionic β-annulus peptide and cationic lipid bilayer.
Furukawa H , Inaba H , Inoue F , Sasaki Y , Akiyoshi K , Matsuura K . Furukawa H , et al. Chem Commun (Camb). 2020 Jul 4;56(52):7092-7095. doi: 10.1039/d0cc02622k. Epub 2020 Jun 3. Chem Commun (Camb). 2020. PMID: 32490862 - Antigen/Adjuvant-Displaying Enveloped Viral Replica as a Self-Adjuvanting Anti-Breast-Cancer Vaccine Candidate.
Ito K, Furukawa H, Inaba H, Ohshima S, Kametani Y, Maeki M, Tokeshi M, Huang X, Kabayama K, Manabe Y, Fukase K, Matsuura K. Ito K, et al. J Am Chem Soc. 2023 Jul 26;145(29):15838-15847. doi: 10.1021/jacs.3c02679. Epub 2023 Jun 21. J Am Chem Soc. 2023. PMID: 37344812 - Activation, exposure and penetration of virally encoded, membrane-active polypeptides during non-enveloped virus entry.
Banerjee M, Johnson JE. Banerjee M, et al. Curr Protein Pept Sci. 2008 Feb;9(1):16-27. doi: 10.2174/138920308783565732. Curr Protein Pept Sci. 2008. PMID: 18336320 Review. - Cryo-electron tomography of enveloped viruses.
Li S. Li S. Trends Biochem Sci. 2022 Feb;47(2):173-186. doi: 10.1016/j.tibs.2021.08.005. Epub 2021 Sep 10. Trends Biochem Sci. 2022. PMID: 34511334 Review.
Cited by
- Engineering cell-free systems by chemoproteomic-assisted phenotypic screening.
Levitskaya Z, Ser Z, Koh H, Mei WS, Chee S, Sobota RM, Ghadessy JF. Levitskaya Z, et al. RSC Chem Biol. 2024 Mar 6;5(4):372-385. doi: 10.1039/d4cb00004h. eCollection 2024 Apr 3. RSC Chem Biol. 2024. PMID: 38576719 Free PMC article. - A supramolecular system mimicking the infection process of an enveloped virus through membrane fusion.
Furukawa H, Kimura Y, Inaba H, Matsuura K. Furukawa H, et al. Sci Rep. 2023 Nov 15;13(1):19934. doi: 10.1038/s41598-023-47347-7. Sci Rep. 2023. PMID: 37968508 Free PMC article. - Hemopexin as a Potential Binding Partner of Arginine-Rich Cell-Penetrating Peptides in Serum.
Nomura K, Kawano K, Kawaguchi Y, Kawamura Y, Michibata J, Kuwata K, Sugiyama K, Kusumoto K, Futaki S. Nomura K, et al. ACS Pharmacol Transl Sci. 2022 Jul 20;5(8):603-615. doi: 10.1021/acsptsci.2c00043. eCollection 2022 Aug 12. ACS Pharmacol Transl Sci. 2022. PMID: 35983275 Free PMC article.
References
- Structure and Physics of Viruses, ed. M. G. Mateu, Springer, 2013
- Virus Structure and Assembly (Advances in Virus Research, vol. 64), ed. P. Roy, Academic Press, 2005
LinkOut - more resources
Full Text Sources